Torres-Escobar Gabriela, González-Pacheco Héctor, Cruz Jose Luis Briseño-De la, Arias-Mendoza Alexandra, Araiza-Garaygordobil Diego
Unidad Coronaria, Instituto Nacional de Cardiología Ignacio Chávez, Secretaría de Salud, Ciudad México, México.
Arch Cardiol Mex. 2020;90(Supl):62-66. doi: 10.24875/ACM.M20000069.
Reperfusion therapy is a measure of care in patients with ST-elevation myocardial infarction (STEMI), which should be performed once we have the diagnosis. Percutaneous coronary intervention is considered the gold standard, however in patients with SARS-CoV-2 infection, the reperfusion strategy is more focused on fibrinolytic therapy due to the shorter time required to perform and less exposure. This pandemic represents a contact problem in health personnel, since cases are increasing worldwide, so it is important to know the measures that must be followed to avoid coronavirus disease (COVID-19).
再灌注治疗是ST段抬高型心肌梗死（STEMI）患者的一种治疗措施，一旦确诊就应实施。经皮冠状动脉介入治疗被认为是金标准，然而对于感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者，由于实施溶栓治疗所需时间较短且暴露较少，再灌注策略更侧重于溶栓治疗。这场大流行给医护人员带来了接触问题，因为全球病例在增加，所以了解必须遵循的预防冠状病毒病（COVID-19）的措施很重要。
